India, April 8 -- Shares of Pacira BioSciences, Inc. (PCRX) jumped over 16% on Tuesday morning after the company announced settlement of U.S. patent litigation for Exparel.
PCRX is currently trading at $26.65, up $3.74 or 16.32%, on the Nasdaq. The stock opened its trading at $27.60 after closing Monday at $22.91. The stock has traded between $11.16 and $31.67 in the past 52-week period.
Pacira BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine liposome injectable suspension).
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); })...